Sl No | Brand | Q1 Revenues |
1 | Keytruda | $6.9 billion |
2 | Ozempic | $4.0 billion |
3 | Dupixent | $3.4 billion |
4 | Biktarvy | $3.0 billion |
5 | Darzalex | $2.7 billion |
6 | Stelara | $2.5 billion |
7 | Humira | $2.3 billion |
8 | Gardasil | $2.2 billion |
9 | Opdivo | $2.1 billion |
10 | Skyrizi | $2.0 billion |
1. Keytruda (Pembrolizumab)
Approved for: Keytruda is approved for treating various types of cancer, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, and more.
Manufacturer: Merck & Co., Inc.
Mechanism of Action: Keytruda is a monoclonal antibody that works by targeting and blocking the PD-1 (programmed death receptor-1) protein on the surface of T-cells. This inhibition boosts the immune system's ability to detect and destroy cancer cells.
2. Ozempic (Semaglutide)
Approved for: Ozempic is approved for managing type 2 diabetes and reducing the risk of major cardiovascular events in adults with type 2 diabetes and known heart disease.
Manufacturer: Novo Nordisk
Mechanism of Action: Ozempic is a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the action of the natural hormone GLP-1, enhancing insulin secretion, suppressing glucagon secretion, and slowing gastric emptying, which together helps control blood sugar levels.
3. Dupixent (Dupilumab)
Approved for: Dupixent is approved for the treatment of moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.
Manufacturer: Regeneron Pharmaceuticals and Sanofi
Mechanism of Action: Dupixent is a monoclonal antibody that inhibits the signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two key cytokines involved in the inflammatory response in various allergic and atopic diseases.
4. Biktarvy (Bictegravir/Emtricitabine/Tenofovir alafenamide)
Approved for: Biktarvy is approved for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg.
Manufacturer: Gilead Sciences
Mechanism of Action: Biktarvy combines three antiretroviral drugs: bictegravir (an integrase strand transfer inhibitor), emtricitabine, and tenofovir alafenamide (both nucleoside reverse transcriptase inhibitors), which together inhibit viral replication at different stages.
5. Darzalex (Daratumumab)
Approved for: Darzalex is approved for treating multiple myeloma, either as a monotherapy or in combination with other therapies.
Manufacturer: Janssen Biotech, Inc.
Mechanism of Action: Darzalex is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells, leading to the destruction of these cancer cells via immune-mediated mechanisms.
6. Stelara (Ustekinumab)
Approved for: Stelara is approved for treating moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Manufacturer: Janssen Biotech, Inc.
Mechanism of Action: Stelara is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), cytokines that are involved in inflammatory and immune responses, thereby reducing inflammation and autoimmune reactions.
7. Humira (Adalimumab)
Approved for: Humira is approved
for treating a variety of inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and juvenile idiopathic arthritis.
Manufacturer: AbbVie Inc.
Mechanism of Action: Humira is a TNF (tumor necrosis factor) inhibitor. It binds to TNF-alpha, a pro-inflammatory cytokine, blocking its interaction with TNF receptors, thereby reducing inflammation and altering the immune response.
8. Gardasil (Human Papillomavirus Vaccine)
Approved for: Gardasil is approved for the prevention of diseases caused by human papillomavirus (HPV) types, including cervical, vulvar, vaginal, and anal cancers, genital warts, and precancerous or dysplastic lesions.
Manufacturer: Merck & Co., Inc.
Mechanism of Action: Gardasil is a vaccine that contains virus-like particles (VLPs) of the L1 protein from various HPV types. It stimulates an immune response against HPV, helping to prevent infection and the development of HPV-related diseases.
9. Opdivo (Nivolumab)
Approved for: Opdivo is approved for treating multiple types of cancer, including melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, and more.
Manufacturer: Bristol-Myers Squibb
Mechanism of Action: Opdivo is a monoclonal antibody that inhibits the PD-1 receptor on T-cells. By blocking this receptor, Opdivo enhances the immune system's ability to recognize and attack cancer cells.
10. Skyrizi (Risankizumab)
Approved for: Skyrizi is approved for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis.
Manufacturer: AbbVie Inc.
Mechanism of Action: Skyrizi is a monoclonal antibody that selectively targets and inhibits interleukin-23 (IL-23), a cytokine involved in the inflammatory process of psoriasis. By blocking IL-23, Skyrizi reduces inflammation and the symptoms of psoriasis.
Comments